Skip to main content

Neil Hocking Joins Gene Logic s New UK Base, William Sullivan VP at Ciphergen s Diagnostics Division, Steven Deitcher Joins Nuvelo as VP for Medical Affairs, John Conley Resigns as Alnylam CFO, and Others

Neil Hocking has become executive director for business development in Europe at Gene Logic's new UK-based subsidiary, the company said today. Previously, he had worked for Sanyo, MDL, and Celera Genomics.


William Sullivan has become vice president of diagnostics operations at Ciphergen's new diagnostics division, the company said on Monday. Before joining Ciphergen, he was vice president of diagnostic manufacturing at Visible Genetics. Sullivan holds an AB degree from the College of the Holy Cross and attended graduate school at the University of Pennsylvania.


Steven Deitcher has become vice president for medical affairs at Nuvelo, the Sunnyvale, Calif.-based company said yesterday. He will be responsible for all aspects of the company's clinical programs. Deitcher comes to Nuvelo from The Cleveland Clinic Foundation, where he was head of hematology and coagulation medicine. He holds an MD and BS from Northwestern University Medical School.


John Conley has resigned his position as CFO at Alnylam, according to a recent Alnylam filing with the US Securities and Exchange Commission. According to the company, Conley's departure became effective Jan. 31.


Gourish Hosangady has been appointed vice president of sales and marketing at TurboWorx, the Burlington, Mass.-based company said yesterday. He joins TurboWorx from SAS India, where he was CEO and managing director.


Bradley Sparks and William Hammond have been appointed to the board of directors of VizX Labs, the Seattle-based bioinformatics company said on Monday.

Sparks, who was also elected chairman of the board, is managing director of Sunburst Growth Ventures, which focuses on emerging biotechnology companies. He was trained in engineering at the US Military Academy, West Point.

Hammond was most recently president, medical director, and CEO of The Hope Heart Institute. He holds an MD from Tufts University and a BA from Harvard University.


Kevin Johnson and Giannni Garotta have joined Index Ventures as executives in residence, and Ennio Ongini as venture advisor, the European venture capital firm said last week.

Johnson was most recently chief technology officer of Cambridge Antibody Technologies.

Garotta used to be vice president for academic collaborations at Serono.

Ongini is currently head of discovery at Nicox.


Cynthia Helphingstine has become vice president of business development for Inproteo. Prior to joining Inproteo, she was a consultant at Biotron Group, which she helped to found.


Debra Hutson has become director of quality assurance, and Steve Owings director of business development for the diagnostics business at Epoch Biosciences, the company said last month.

Hutson was formerly director for quality assurance of manufacturing at CombiMatrix.

Owings was vice president of sales and marketing at Visible Genetics, which was acquired by Bayer Diagnostics in 2002.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.